MorphoSys Licenses Genedata Biologics Data Management Platform
Leader in therapeutic antibodies adopts Genedata Biologics for its central research and development IT infrastructure
September 27, 2011
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that MorphoSys AG will license Genedata Biologics™ as its R&D data management platform. MorphoSys, a pioneer in the field of therapeutic antibodies, will use Genedata Biologics to support internal and partner-based biologics discovery programs for lead finding and optimization. Genedata Biologics integrates with the MorphoSys laboratory infrastructure and interacts with proprietary discovery technologies, including the MorphoSys HUCAL® antibody library, screening, and expression platforms.
“Therapeutic antibodies are one of the fastest-growing drug classes in human healthcare,” said Dr. Markus Enzelberger, vice president and head of Discovery Alliances and Technologies at MorphoSys. “To advance our leadership in this field, our biopharma R&D operations require an integrated and scalable informatics infrastructure that can be tailored to support our biologics discovery processes. Genedata Biologics provides comprehensive biologics data management functionality and the flexibility needed to support our proprietary antibody discovery processes and technology portfolio. And, it provides this functionality out-of-the-box, which saves valuable research time and money.”
First-in-Class Biologics Data Management
Genedata Biologics is the industry’s first-in-class biologics data management system. Out-of-the-box, it processes and manages data from diverse library, selection, screening, and expression technologies and strategies. It provides end-to-end laboratory workflow support, spanning: library registration; selection and planning; screening; hit selection; expression; purification; and analytics.
The system’s integrated decision support tools enable the identification of the most promising molecules for development. These tools also provide transparent guidance for downstream expression, purification, characterization, and assessment of candidate molecules.
Inherently flexible, Genedata Biologics is easily configured to address corporate-specific and proprietary workflows and technology requirements. This is accomplished by an integrated yet open molecule and sample management platform, and interfaces for assay and analytics instrument integration. A comprehensive set of APIs enables integration with existing corporate IT infrastructures.
“MorphoSys is pioneering antibody discovery and we are delighted they have selected Genedata Biologics as their central discovery IT infrastructure,” said Dr. Othmar Pfannes, CEO of Genedata. “MorphoSys’ adoption of Genedata Biologics is another major milestone for our growing biopharma business. We will continue to invest in the advancement of protein therapeutics, and support those engaged in the field including pharmaceutical and biotechnology companies, technology providers, CROs, CMOs, and emerging biosimilar companies.”
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.